Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners “Thibelo TB” Aurum Health Research LSHTM JHU Gold.

Slides:



Advertisements
Similar presentations
TB/HIV Research Priorities: TB Preventive Therapy.
Advertisements

Of South Africa DOTS WORKS VWSA WORKPLACE PROGRAM.
Tuberculosis in Children: Prevention Module 10C - March 2010.
High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa – Implications for HIV and TB Treatment Programs Kogieleum Naidoo on behalf.
Effectiveness of the National PMTCT Program in Rwanda
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Utilizing Facility Data for Program Monitoring Valerie Koscelnik Track 1 ART Program Meeting Maputo, August 12, 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
S AFETY OF I SONIAZID P REVENTIVE T HERAPY A MONG HIV- INFECTED P REGNANT W OMEN IN H IGH TB I NCIDENCE S ETTINGS : STUDY UPDATE OF IMPAACT P1078 (APPRISE)
Tuberculosis in the UK 2013 report
Early Detection of breast cancer Anthony B. Miller, MD, FRCP Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, Canada.
Decentralization of HIV care and treatment services in Central Province, Kenya: Adult patient characteristics and outcomes Presenting author: William Reidy,
Sensitivity, specificity and predictive values of symptoms to detect tuberculosis in the ZAMSTAR community based prevalence studies Peter Godfrey-Faussett.
Unit 5: IPT Isoniazid TB Preventive Therapy
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
Southern Africa out of control Swaziland South Africa Namibia Botswana Zimbabwe Lesotho Zambia
Culture Conversion and Self- Administered Therapy in Privately Managed Tuberculosis Patients Melissa Ehman MPH, Jennifer Flood MD MPH, Pennan Barry MD.
Current international guidelines recommend 6–9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in.
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
Surveillance of HIV infection
Treatment as prevention: a new paradigm for HIV control? Richard Hayes.
Impact of tuberculosis screening and isoniazid preventive therapy on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study B. Durovni1,2,
Module 14: Isoniazid Preventive Therapy Programme.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Effectiveness of Micronutrient-rich Lipid Nutrient Supplements in Delaying Clinical Progression of HIV in Malawian Adults Heidi Sandige, MD.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.
Johns Hopkins Center for Tuberculosis Research
Embedding Open-label PrEP trial in expansion of UK HIV Prevention Programme.
Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
TB-HIV INTEGRATION IN THE WORKPLACE 2 nd Private Sector Conference on HIV and AIDS Presenter: Dr S Charalambous.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
CREATE Biostatistics Core THRio Statistical Considerations Analysis Plan.
The revised TB/HIV indicators and update on the process of harmonization Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
MISSING DATA IN THE INFECTIOUS DISEASES INSTITUTE CLINIC DATABASE Agnes N Kiragga East Africa IeDEA investigators’ meeting 4-5 th May 2010 East African.
Clinical Trials and Research A Guide for Community Advisory Board Members Participant Manual.
Africa Impact Evaluation Program on AIDS (AIM-AIDS) Cape Town, South Africa March 8 – 13, Steps in Implementing an Impact Evaluation Nandini Krishnan.
Data Management ZAMSTAR: from preparation to using it … Year 3: Kathy, Nkatya, Ab ZAMSTAR.
Indiaclen Short course of Amoxicillin in treatment of Pneumonia (ISCAP) 3 versus 5 days amoxicillin for treatment of non-severe pneumonia in young children:
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
Thibela TB Trisha Crawford James Lewis Katherine Fielding.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
COSTS STUDY OF SEVERE PNEUMONIA IN AN EQUIVALENCE TRIAL OF ORAL AMOXICILLIN VERSUS INJECTABLE PENICILLIN IN CHILDREN AGED 3 TO 59 MONTHS Patel AB, APPIS.
XVII Annual International AIDS Conference SHAZ! Shaping the Health of Adolescents in Zimbabwe Mudekunye, S. Laver University of Zimbabwe-University of.
ZAMSTAR restricted randomisation CREATE Investigators Meeting 2005 Charalambos (Babis) Sismanidis LSHTM.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
A Way out of Directly Observed Therapy (DOT): Community approaches to Self-Administered Treatment for Rifampicin Resistant Tuberculosis in Khayelitsha,
TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
Participants 18year old+
Jessica Haberer, MD, MS July 24, 2017
On behalf of The MTN-020/ASPIRE Study Team
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
World Health Organization
Progress in Implementation of TB/HIV Collaborative activities
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Effect of POC CD4 testing at HIV diagnosis on attrition prior to ART initiation among youth in Khayelitsha, South Africa Pre-treatment losses to care remains.
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Tuberculosis Global Epidemiology
C R E A E Consortium to Respond Effectively to the AIDS-TB Epidemic
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
South Africa: From ProTest to Nationwide Implementation
From ProTEST to Nationwide Implementation
A randomized, controlled trial of a patient-centered disclosure counseling intervention for Kenyan children living with HIV. Rachel C. Vreeman, MD, MS;
Presentation transcript:

Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners “Thibelo TB” Aurum Health Research LSHTM JHU Gold mining companies Dept. of Health, SA

Study outline To investigate the effect of community-wide TB preventive therapy (TBPT) in setting of high HIV prevalence (gold mines in South Africa) Community randomised controlled study community-wide TBPT vs. standard TB control (targeted TBPT for high risk groups) Community = mine shaft(s) and associated hostel Paired design

Study outline (2) Primary outcome: TB incidence measured 12 months after enrolment (over a 12 month period) Secondary outcomes – TB incidence among HIV infected individuals, measured 12 months after enrolment (over a 12 month period) –TB case notifications, over the 24 month period –TB culture prevalence at the end of the follow-up period

Study month Recruitment of clusters Prevalence survey Primary outcome measurement period 9 months of TBPT Measure primary outcome over 12 months, from months after enrolment Enrol clusters over 15 months 9 months of TBPT

Eligibility criteria for communities Expanded DOTS program which includes –Active TB case finding using chest x-ray –Standardised monitoring and reporting VCT – same-day confidential testing and counselling –Individuals found to be HIV-infected are offered referral for HIV care Isoniazid and cotrimoxazole preventive therapy for HIV-infected individuals

Baseline data TB case notifications rates measured over the 6 month preparation phase Baseline Survey (at recruitment) –Sampling ~ include everyone on certain days ? –TB and silicosis prevalence (using latest chest x-ray) measured at the time of recruitment from a random sample [n=1000 per cluster] –Baseline HIV prevalence (using saliva) measured at the time of recruitment from a random sample [n=1000 per cluster]

Paired versus stratified design? Important confounders are –Baseline TB case notification rates –Prevalence of HIV infection –Prevalence of silicosis –Baseline TB prevalence –Trends in the proportion of the HIV-infected workforce receiving ART over the study period Paired design –mining company and baseline TB case rates

Sample Size (1) Primary outcome: TB incidence over 12 months, measured amongst hostel dwellers –90% power, type I error of 5% –K=0.25, paired design –Average community size of 2500 (80% live in hostels) –Factored in a potential effect of ART –Assumed a 60% reduction in the community wide PT arm Indicates 7 matched pairs

Sample Size (2) Secondary outcomes: –80% power, type I error of 5%, K=0.25, paired design –Average community size of 2500 –Factored in a potential effect of ART HIV-specific TB incidence ~ 60% reduction in the community wide PT arm (over 12 months) TB case notification rates ~ 50% reduction in the community wide PT arm (over 24 months) TB culture prevalence ~ 50% reduction in the community wide PT arm, based on community size of 750

Enrolment Intervention and control enrolment teams will work at one pair of clusters at a time Both arms –Consent to use data –Baseline survey [previous x-ray for TB radiological prevalence and silicosis score; saliva sample for HIV testing] Intervention arm –Symptom screen

Intervention (1) TB screening to exclude active TB using symptom questionnaire and new and previous chest x-ray Investigated further if new abnormality or symptoms All consenting participants offered 9 months of IPT Monthly visits to Dispense IPT Monitoring for toxicity and side effects

Intervention (2) IPT adherence enhancing measures –Patient education –Self-adherence –Treatment supporters –incentives? Monitoring of adherence to IPT –Questionnaire (monthly); pill count etc –Urine testing for INH

Measuring primary outcome TB incidence measured over a 12 month period Human Resources –List of miners living at each hostel (cluster) –Redundancies and death information TB database –All TB diagnoses collected –Case definitions applied

Measuring secondary outcomes TB incidence measured over a 12 month period, amongst HIV-infected As before All TB diagnoses will be offered anonymous- unlinked HIV testing Use the HIV prevalence from baseline survey

Measuring secondary outcomes (2) TB case notification rates over a 24 month period Human Resources (info. collected every 6 mths) –List of miners living at each hostel (cluster) –Redundancies and death information TB database –All TB diagnoses collected Also calculate TB case notification in four 6 month intervals

Statistical Analysis Unadjusted Analysis Point estimate (GM of the pairwise estimates) –Log(RR)=(1/c)∑log(RR j )=(1/c) ∑log(r 1j /r 0j ) where r 1j = TB incidence in cluster j, intervention arm and r 0j = TB incidence in cluster j, control arm –And 95% CI Paired t test, applied to the log(rates)

Statistical Analysis (2) Poisson regression model fitted to the individual data, including all a priori confounders and an indicator variable for matched pairs Calculate the observed (O ij ) and fitted (E ij ) numbers of TB events for each cluster Calculate the GM of O ij /E ij

Other Issues Document TBPT use in the control arm (though the “Wellness” clinics offering care for HIV- infected individuals Pilot study of quantiferon & TST to measure TB infection